ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Jounce Therapeutics Receives FDA Clearance of Investigational NDA for Anti-CCR8 Antibody americanpharmaceuticalreview
June 17, 2021Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the U.S. FDA's clearance of its Investigational New Drug (IND) application for JTX-1811 ... -
Celgene licenses antibody JTX-8064 from Jounce for $50m pharmaceutical-technology
July 25, 2019Global biopharma company Celgene has updated its 2016 strategic collaboration with clinical stage-focused Jounce Therapeutics and has decided to license global rights to JTX-8064; Celgene will now be responsible for all development and commercialisation o
Pharma Sources Insight January 2025
